Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 8 (4), 278-87

Distribution of IL-28B Genotypes in Patients With Hepatitis C and Healthy Individuals in Jahrom City


Distribution of IL-28B Genotypes in Patients With Hepatitis C and Healthy Individuals in Jahrom City

Seyed Dawood Mousavi Nasab et al. Gastroenterol Hepatol Bed Bench.


Aim: The purpose of this study was to compare the distribution of interleukin (IL)-28B genotypes between Iranian healthy individuals and patients with chronic hepatitis C based on the genotype.

Background: Polymorphisms in the region of IL-28B gene have been identified as the strongest genetic pretreatment predictor of sustained virological response (SVR) in hepatitis C infection.

Patients and methods: In this study, 147 patients with chronic hepatitis C and 80 healthy individuals were included. The IL-28B rs12979860 and rs8099917 polymorphisms were genotyped by PCR-RFLP method and the frequency of IL-28B polymorphisms with respect to HCV genotypes was also determined.

Results: The frequencies of rs12979860 TT, CC and CT genotypes in the chronic hepatitis C patients and healthy individuals were as follows: 10.8% vs. 11.3%, 38.7% vs. 46.2% and 50.3% vs. 42.5%. Also, the frequencies of rs8099917 TT, GG and GT genotypes in the chronic hepatitis C patients was 61.9%, 6.1% and 32% and in controls was 47.5%, 11.2% and 41.3%. The differences in the distribution of rs12979860 genotypes and alleles between HCV genotype 1 and HCV genotype 3a infected patients were statistically significant.

Conclusion: The rs12979860 C allele is the favorable allele for the spontaneous clearance of HCV. It seems that the impact of IL-28B polymorphism on the spontaneous clearance of HCV genotype 3 is more prominent than HCV genotype 1, which results in the observation of higher rs12979860 C allele frequency in chronic hepatitis C patients with HCV genotype 3 than HCV genotype 1.

Keywords: Hepatitis C; IL-28B Genotype; Jahrom; Polymorphism.


Figure 1
Figure 1
Typical electrophoresis patterns of PCR products from different HCV genotypes. Patterns of four serum samples left to right are shown for containing HCV genotypes 1a (lane 5), 1b (lane 2), 3a (lanes 4 and 6), Mix genotype 2/3a (lane 8) and 1a/1b (line 7). The patterns of molecular size markers (GeneRuler™ 100 bp Plus DNA Ladder, ready-to-use; Fermentas UAB, Vilnius, Lithuania) are indicated on lane 1. The lengths of PCR products were 338 bp for genotype 1a, 398 bp for 1b, 286 bp for 2 and 227 bp for 3a
Figure 2
Figure 2
rs12979860 PCR-RFLP genotyping. Digestion of this product with Bstu І in CC individuals produced 3 fragments of 135bp, 82bp, 25bp; 4 fragments of 160bp, 135bp, 82bp , 25bp in CT individuals; and 2 fragment of 160bp , 82bp in TT individuals. Lanes no. 1 was genotyped TT, 2, 3, 4, 7 & 8 were genotyped CC, lane no. 5 & 6 were genotyped CT

Similar articles

See all similar articles

Cited by 3 PubMed Central articles


    1. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. I. J Med Sci. 2006;3:47–52. - PMC - PubMed
    1. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13:34–41. - PubMed
    1. McHutchison JG, Jawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–93. - PubMed
    1. Adziyannis SJ, Sette H JR, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;40:346–55. - PubMed
    1. Fried MW, Hadziyannis SJ. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Semin Liver Dis. 2004;24:47–54. - PubMed

LinkOut - more resources